Trial · NCT05823675
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment Emergent Adverse Events | Study Day 85 | Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
| Secondary | Time to maximum Itolizumab serum concentration, Tmax | Study Day 85 | Time to maximum Itolizumab serum concentration |
| Secondary | Maximum Itolizumab serum drug concentration, Cmax | Study Day 85 | Maximum Itolizumab serum drug concentration |
| Secondary | Minimum Itolizumab serum drug concentration, Cmin | Study Day 85 | Minimum Itolizumab serum drug concentration |
| Secondary | Total Itolizumab exposure across time, AUC | Study Day 85 | Total Itolizumab exposure across time, AUC |
| Secondary | Half life of Itolizumab, t1/2 | Study Day 85 | Half life of Itolizumab |
| Secondary | Volume of distribution of Itolizumab, Vd | Study Day 85 | Volume of distribution of Itolizumab |
| Secondary | Clearance, Cl | Study Day 85 | Clearance |
| Secondary | CD6 receptor expression levels on T cells | Study Day 85 | CD6 receptor expression levels |
| Secondary | T cell subsets | Study Day 85 | T cell subsets |
| Secondary | Inflammatory Markers | Study Day 85 | Including but not limited to:IL-2, IL-6, IL-8, IL-17, IFN-γ, TNF-α, CRP, TNFR1, ST2, REG3α, Elafin |
| Secondary | Overall Response Rate (ORR) | Study Day 337 | Percentage of subjects demonstrating a CR or PR. |
| Secondary | Nonrelapse Mortality(NRM) Rate | Study Day 337 | Proportion of subjects who died due to causes other than malignancy relapse |
| Secondary | cGVHD rate | Study Day 337 | Percentage of subjects demonstrating of cGVHD |
| Secondary | Dose Reduction in Systemic Steroid Use | Study Day 337 | Change from Baselinein Dose of Systemic Steroid Use |
| Secondary | Incidence of ADA | Study Day 85 | Precentage of subjects presenting anti-drug antibody |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05823675/registered